Gorlin syndrome: genes and variants
Explore variant evidence for Gorlin syndrome across 2 analyzed proteins (PTCH1, SUFU). Linked ClinVar records include 27 pathogenic or likely pathogenic variants, 1,863 variants of uncertain significance and 494 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Gorlin syndrome
PTCH1: Protein patched homolog 1
It suppresses Smoothened in the absence of Hedgehog ligands and thereby keeps Hedgehog developmental signaling inactive until an appropriate signal is received. Germline loss-of-function variants cause Gorlin syndrome, while somatic pathway activation drives basal-cell carcinoma and other tumors.
27 ClinVar pathogenic / likely pathogenic and 1,834 uncertain variants in PTCH1 have source records linked to Gorlin syndrome. Association strength is not clinical gene validity.
SUFU: Suppressor of fused homolog
It restrains GLI transcription factors and thereby keeps Hedgehog signaling off when pathway activation is absent. Germline loss-of-function variants predispose particularly to infant desmoplastic medulloblastoma and can also cause developmental Hedgehog-pathway phenotypes.
0 ClinVar pathogenic / likely pathogenic and 523 uncertain variants in SUFU have source records linked to Gorlin syndrome. Association strength is not clinical gene validity.
Where Gorlin syndrome variants cluster
- PTCH1 Transmembrane (positions 501–519): 6 of 26 ClinVar pathogenic / likely pathogenic variants, 17.6× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Gorlin syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| PTCH1 G509D | 509 | SSD | Pathogenic / likely pathogenic (★★) |
| PTCH1 G509V | 509 | SSD | Pathogenic / likely pathogenic (★★) |
| PTCH1 Q501H | 501 | SSD | Pathogenic / likely pathogenic (★★) |
| PTCH1 A569D | 569 | SSD | Pathogenic / likely pathogenic (★★) |
| PTCH1 S1132F | 1132 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| PTCH1 W129R | 129 | Extracellular domain 1 (ECD1) | Pathogenic / likely pathogenic (★★) |
| PTCH1 S554R | 554 | SSD | Pathogenic / likely pathogenic (★★) |
| PTCH1 P681L | 681 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| PTCH1 G1136R | 1136 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| PTCH1 L1156R | 1156 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| PTCH1 G1167R | 1167 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| PTCH1 G509R | 509 | SSD | Pathogenic / likely pathogenic (★) |
| PTCH1 W844C | 844 | Extracellular domain 2 (ECD2) | Pathogenic / likely pathogenic (★) |
| PTCH1 W844S | 844 | Extracellular domain 2 (ECD2) | Pathogenic / likely pathogenic (★) |
| PTCH1 W844R | 844 | Extracellular domain 2 (ECD2) | Pathogenic / likely pathogenic (★) |
| PTCH1 G445R | 445 | SSD | Pathogenic / likely pathogenic (★) |
| PTCH1 G511R | 511 | SSD | Pathogenic / likely pathogenic (★) |
| PTCH1 E237K | 237 | Extracellular domain 1 (ECD1) | Pathogenic / likely pathogenic (★) |
| PTCH1 C304R | 304 | Extracellular domain 1 (ECD1) | Pathogenic / likely pathogenic (★) |
| PTCH1 G484R | 484 | SSD | Pathogenic / likely pathogenic (★) |
| PTCH1 L487R | 487 | SSD | Pathogenic / likely pathogenic (★) |
| PTCH1 T499R | 499 | SSD | Pathogenic / likely pathogenic (★) |
| PTCH1 P504Q | 504 | SSD | Pathogenic / likely pathogenic (★) |
| PTCH1 W926S | 926 | Extracellular domain 2 (ECD2) | Pathogenic / likely pathogenic (★) |
| PTCH1 G1093R | 1093 | Transmembrane | Pathogenic / likely pathogenic (★) |
| PTCH1 G1163R | 1163 | Transmembrane | Pathogenic / likely pathogenic (★) |
| PTCH1 R195K | 195 | Extracellular domain 1 (ECD1) | Pathogenic / likely pathogenic (★) |
Uncertain variants prioritized for review in Gorlin syndrome
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| PTCH1 A569T | 569 | SSD | Uncertain (★★) | +7: in a 3D region that tolerates change poorly (2R); A569D at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.874 |
| PTCH1 A569V | 569 | SSD | Uncertain (★) | +7: in a 3D region that tolerates change poorly (2R); A569D at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.872 |
| PTCH1 T499I | 499 | SSD | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; T499R at the same position is pathogenic; seen in 6.6e-06 of gnomAD DNA copies; REVEL 0.776 |
| PTCH1 G445D | 445 | SSD | Uncertain (★★) | +6: in a 3D region that tolerates change poorly (2R); G445R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| PTCH1 T499K | 499 | SSD | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; T499R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| PTCH1 A569G | 569 | SSD | Uncertain (★) | +6: in a 3D region that tolerates change poorly (2R); A569D at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.81 |
| PTCH1 G445S | 445 | SSD | Uncertain (★★) | +6: in a 3D region that tolerates change poorly (2R); G445R at the same position is pathogenic; seen in 4.8e-06 of gnomAD DNA copies; REVEL 0.756 |
Which prediction tools work for Gorlin syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 98 out of 100
- PolyPhen-2: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 94 out of 100
- MetaLR: 93 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 93 out of 100
- SIFT: 91 out of 100
Diseases related to Gorlin syndrome
- Medulloblastoma, also linked to PTCH1 and SUFU
- Basal cell nevus syndrome, also linked to PTCH1 and SUFU
- Ovarian cancer, also linked to PTCH1
- Joubert syndrome, also linked to SUFU
- Familial meningioma, also linked to SUFU
- Basal cell carcinoma, also linked to PTCH1
- Holoprosencephaly, also linked to PTCH1
Frequently asked questions
Which genes have records linked to Gorlin syndrome?
This view contains 2 analyzed proteins: PTCH1, SUFU. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 27 pathogenic or likely pathogenic variants, 1,863 variants of uncertain significance and 494 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 7 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 2,524 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center